Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union-Reference-Cited by-同舟云学术

Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union

Published:2017-01-21 Issue:1 Volume:12 Page:
ISSN:1750-1172
Container-title:Orphanet Journal of Rare Diseases
language:en
Short-container-title:Orphanet J Rare Dis

Author:

Polsinelli Benedetta,Tsigkos Stelios,Naumann-Winter Frauke,Mariz Segundo,Sepodes Bruno^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Genetics (clinical),General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13023-017-0567-7.pdf

Reference11 articles.

1. Sant M, E.-5. W. Group. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931–42.

2. Opinions for Rare disease (orphan) designations. Eur Med Agency, [Online]. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan_search.jsp&mid=WC0b01ac058001d12b . Accessed 21 Sept 2016

3. Survival of cancer patients in Europe. Eurocare, [Online]. Available: http://www.eurocare.it/ . Accessed 25 Aug 2016

4. Statistics for haematological malignancies. Haematol Malig Res Netw, [Online]. Available: http://www.hmrn.org/statistics . Accessed 25 Aug 2016

5. COMP: Agendas, minutes and meeting reports. Eur Med Agency, [Online]. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000201.jsp&mid=WC0b01ac0580028e78#section2 . Accessed 21 Sept 2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma;Blood;2024-07-25

2. Chronic Lymphocytic Leukemia;Holland‐Frei Cancer Medicine;2022-10-21

3. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia;Expert Review of Hematology;2022-03-04

4. Regulatory Standards in Orphan Medicinal Product Designation in the EU;Frontiers in Medicine;2021-06-25

5. EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia;HemaSphere;2020-12-29